Prelude Therapeutics Inc (PRLD) Financial Statements

PRLD Financial Data

EBITDA$-96.25M

Revenue (TTM)$12.14M

Gross Profit (TTM)$12.14M

Gross Margin—

Operating Margin-861.33%

ROE-144.96%

ROA-70.41%

Debt/Equity0.26

Current Ratio1.99

FCF$-56.37M

FCF Yield-18.92%

Piotroski F-Score—

Rev/Share (TTM)$0.19

50-Day MA$3.72

200-Day MA$2.12

Shares Outstanding0.06B

PRLD Computed Insights

FCF$-56.37M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

PRLD Financial Statements & Data

Prelude Therapeutics Inc (PRLD) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Prelude Therapeutics Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $12.14M. Gross profit (TTM) is $12.14M. EBITDA is $-96.25M. Earnings per share (EPS) is $-1.29. The P/E ratio is -2.99. Market capitalization is $297.98M.

Free cash flow (FCF) is $-56.37M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Prelude Therapeutics Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.